Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR402663 in Neovascular Age-related Macular Degeneration
NCT06660667Phase 2Active, not recruiting
- Sponsor
- Sanofi
- Start
- Nov 2024
- Primary completion
- May 2027
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of SAR402663 in neovascular age-related macular degeneration (NVAMD) (3 arms), sponsored by Sanofi. Primary endpoints: Incidence and severity of ocular treatment emergent adverse event (TEAEs), Incidence and severity of ocular treatment emergent serious adverse event (TESAEs) and 4 more. Started Nov 2024; status: active, not recruiting.
02
Drugs
SAR402663
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT06660667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06660667.